JBIO Earnings Date: Nov 12, 2026 (Estimated) — Jade Biosciences, Inc.

NASDAQ · Healthcare · Biotechnology

Updated

Price $14.19
Market Cap $902.1M
P/E -5.2
52W Range $8.36 – $28.00
Next Earnings · Before open (est.)

When is JBIO's next earnings date?

Jade Biosciences, Inc. (JBIO) is expected to report Q3 2026 earnings on Thursday, November 12, 2026 at 4:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.73.

How did JBIO do in its last earnings report?

In its most recent report on Aug 10, 2026 (Q2 2026), Jade Biosciences, Inc. posted EPS of -$0.76 versus the -$0.64 estimate, a miss of 33.3%. Revenue was $0. The stock's 1-day post-earnings move was -1.0%.

How much does JBIO stock move after earnings?

JBIO beat EPS estimates in 2 of its last 5 reported quarters. Over the last 5 reports the stock moved an average of 3.9% (up or down) in the day after earnings.

About Jade Biosciences, Inc.

Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.

Earnings History

DatePeriodEPS Est.EPS Act.SurpriseRevenueResult1D Δ1W Δ1M Δ
2026-08-10Q2 2026-0.64-0.76-33.33%$0❌ Miss-1.05%+12.52%-11.43%
2026-05-07Q1 2026-0.49-0.57-16.33%$0❌ Miss+6.56%-0.37%-38.15%
2026-03-06Q4 2025-0.46-0.11+76.09%$0✅ Beat+1.22%-0.14%+16.50%
2025-11-13Q3 2025-0.63-0.48+23.81%$0✅ Beat-3.20%+24.60%+49.80%
2025-08-13Q2 2025-0.43-0.86-100.00%$0❌ Miss-7.64%-6.55%+5.05%

Showing last 5 quarters.

Related Companies

Learn More

Explore More

Financial data from licensed market-data providers; risk factors from SEC EDGAR filings. AI-powered analysis. Data last updated .